Cancer Molecular Imaging

癌症分子成像项目区由18名成员组成，横跨7个部门 加州大学洛杉矶分校。在过去的竞争周期中，该项目的调查人员撰写了265份出版物，其中232份 (88%)是方案间的，89(34%)是方案内的。71人(27%)处于高冲击状态 我们的家人。此计划区域的9个成员使用了当前资助的8个共享资源中的6个 由JCCC提供。在本供资年度，同行审查供资的总费用为440万美元， 其中包括来自国家癌症研究所的380万美元。与其他计划领域一样，JCCC培养了 支持CMI调查人员的互动活动的数量和许多共享资源 节目区。在当前的赠款周期内，JCCC以CCSG Development的形式提供的资金 向CMI项目区提供的资金、机构支持和慈善捐赠总额为317,584美元。这些资金 支持种子资助、招聘/保留和计划领域领导支持。四个计划领域 成员是JCCC支持的接受者。 分子成像是一套强大的方法来揭示活体受试者的功能变化 使人们能够对人类健康和疾病有令人信服的洞察力。新提出的JCCC肿瘤分子 成像程序区将研究人员聚集在一起，共同专注于使用分子成像 研究活体癌症的工具，从实验室啮齿动物模型到病人。CMI的努力 调查人员围绕四个主要主题进行组织。1)仪器和分析技术的发展 工具。推动分子成像向前发展需要不断发展和改进仪器 为生物分子和过程提供更高的分辨率、灵敏度和定量测量 在活体内。2)发展新的分子成像方法。CMI项目区成员已被 在分子成像领域处于领先地位，在新型示踪剂、成像基因方面做出了重大贡献 利用报告基因表达，开发动物模型来开发非侵入性的优势， 重复和定量成像，以及多模成像仪器和分析的发展 程序。这些工具被用于研究癌症的起始和进展、转移扩散和 临床前模型中的治疗反应。3)成像免疫反应和对 免疫疗法。CMI计划领域的一个重要焦点是开发监测免疫的工具 在活着的个体中对癌症免疫治疗的反应和跟踪效果。4)影象翻译 将技术应用于癌症患者的临床环境。最终，CMI计划领域的目标是 提高对癌症的认识、检测和治疗水平。CMI计划领域成员追求 翻译目标，包括确定当前可用的分子示踪剂在 临床应用(如FDG-PET、Flt-PET)以及通过临床评估翻译新的分子示踪剂。

The Cancer Molecular Imaging Program Area is composed of 18 members, spanning 7 Departments within UCLA. In the past competing cycle, investigators from this Program authored 265 publications, of which 232 (88%) were inter-programmatic and 89 (34%) intra-programmatic. 71 (27%) were placed in high-impact ournals. Nine members of this Program Area used 6 out of the 8 Shared Resources that are currently funded by the JCCC. During the current funding year, peer-reviewed funding totaled $4.4 million in total costs, including $3.8 million from the National Cancer Institute. As with other Program Areas, JCCC fosters a number of interactive activities and many of the Shared Resources that support investigators in the CMI Program Area. During the current grant cycle, funds from the JCCC in the form of CCSG Developmental Funds, institutional support and philanthropic gifts to the CMI Program Area total $317,584. These funds supported Seed Grants, recruitment/retention & Program Area Leadership support. Four of the Program Area Members were the recipients of JCCC support. Molecular imaging is a powerful set of approaches to reveal functional changes in living subjects that has enabled compelling insights into human health and disease. The newly proposed JCCC Cancer Molecular Imaging Program Area brings together investigators with a common focus on employing molecular imaging tools to investigate cancer in living individuals, from laboratory rodent models to patients. The efforts of CMI investigators are organized around four main themes. 1) Development of instrumentation and analytical tools. Moving molecular imaging forward requires constant development and improvement in instrumentation to provide higher resolution, sensitivity, and quantitative measurement of biological molecules and processes in vivo. 2) Development of novel molecular imaging approaches. CMI Program Area members have been leaders in the field of molecular imaging, with significant contributions in novel tracers, imaging gene expression using reporter genes, developing animal models to exploit the advantages of non-invasive, repeated and quantitative imaging, and in development of multimodality imaging instrumentation and analytic procedures. These tools are employed in the study of cancer initiation and progression, metastatic spread, and response to treatment, in preclinical models. 3) Imaging immune responses and response to immunotherapy. An important focus of the CMI Program Area is to develop the tools to monitor immune responses and follow the effects of cancer immunotherapy in living individuals. 4) Translation of imaging technologies to clinical contexts for cancer patients. Ultimately, the goal of the CMI Program Area is to improve the understanding, detection, and treatment of cancer. CMI Program Area members pursue translational goals that include both determining the best use of currently available molecular tracers in the clinic (e.g., FDG-PET, FLT-PET) as well as translating new molecular tracers through clinical evaluation.